India, June 17 -- Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in pancreatic cancer trial; Lunai, after its CEO issued a letter to shareholders outlining the developments in the company; and Polyrizon, which announced the publication of a U.S. patent application for its nasal drug delivery technology, among others.
Read on.
QURE Surges on Positive FDA Surprise
uniQure N.V. (QURE), a gene therapy company, has been informed by the FDA that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a Biologics License Application for the ...